1. Roth, L.M. et al. (2006) Recent advances in the pathology and clas- sification of ovarian germ cell tumors. Int. J. Gynecol. Pathol., 25, 305–320.
2. Hackethal, A. et al. (2008) Squamous-cell carcinoma in mature cystic teratoma of the ovary: systematic review and analysis of published data. Lancet. Oncol., 9, 1173–1180.
3. Rathore, R. et al. (2018) Malignant transformation in mature cystic tera- toma of the ovary: a retrospective study of eight cases and review of literature. Prz. Menopauzalny, 17, 63–68.
4. Trabzonlu, L. et al. (2017) Malignant tumors associated with ovarian mature teratoma: a single institution experience. Pathol. Res. Pract., 213, 518–521.
5. Kurman, R.J. et al. (2014) WHO Classification of Tumours of Female Reproductive Organs. 4th edn. IARC press, Lyon.
6. Kikkawa, F. et al. (1998) Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary. Cancer, 82, 2249–2255.
7. Chen, R.J. et al. (2008) Prognosis and treatment of squamous cell car- cinoma from a mature cystic teratoma of the ovary. J. Formos. Med. Assoc., 107, 857–868.
8. Sakuma, M. et al. (2010) Malignant transformation arising from ma- ture cystic teratoma of the ovary: a retrospective study of 20 cases. Int. J. Gynecol. Cancer, 20, 766–771.
9. Do, V.T. et al. (2001) Postoperative concurrent chronomodulated 5-fluorouracil/leucovorin infusion and pelvic radiotherapy for squa- mous cell carcinoma of the ovary arising from mature cystic teratoma. Int. J. Gynecol. Cancer, 11, 418–421.
10. Yoshida, K. et al. (2016) Radiotherapy for persistent malignant trans- formation from mature cystic teratoma of the ovary. J. Obstet. Gynaecol. Res., 42, 584–588.
11. Yoshioka, T. et al. (1998) Immunohistochemical and molecular studies on malignant transformation in mature cystic teratoma of the ovary. J. Obstet. Gynaecol. Res., 24, 83–90.
12. Iwasa, A. et al. (2007) Squamous cell carcinoma arising in mature cystic teratoma of the ovary: an immunohistochemical analysis of its tumorigenesis. Histopathology, 51, 98–104.
13. Iwasa, A. et al. (2008) Malignant transformation of mature cystic tera- toma to squamous cell carcinoma involves altered expression of p53- and p16/Rb-dependent cell cycle regulator proteins. Pathol. Int., 58, 757–764.
14. Paliogiannis, P. et al. (2014) Squamous cell carcinoma arising in mature cystic teratoma of the ovary: report of two cases with molecular ana- lysis. Eur. J. Gynaecol. Oncol., 35, 72–76.
15. Chiang, A.J. et al. (2015) Detection of human papillomavirus in squa- mous cell carcinoma arising from dermoid cysts. Taiwan. J. Obstet. Gynecol., 54, 559–566.
16. Ambros, V. (2004) The functions of animal microRNAs. Nature, 431, 350–355.
17. Bartel, D.P. (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281–297.
18. Nana-Sinkam, S.P. et al. (2011) MicroRNAs as therapeutic targets in cancer. Transl. Res., 157, 216–225.
19. Chen, C.Z. (2005) MicroRNAs as oncogenes and tumor suppressors. N. Engl. J. Med., 353, 1768–1771.
20. Lu, J. et al. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834–838.
21. Tsuchiya, Y. et al. (2006) MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res., 66, 9090–9098.
22. Motameny, S. et al. (2010) Next generation sequencing of miRNAs— Strategies, resources and methods. Genes (Basel)., 1, 70–84.
23. Yokoi, A. et al. (2017) A combination of circulating miRNAs for the early detection of ovarian cancer. Oncotarget, 8, 89811–89823.
24. Yokoi, A. et al. (2018) Integrated extracellular microRNA profiling for ovarian cancer screening. Nat. Commun., 9, 4319.
25. Griffiths-Jones, S. et al. (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res., 36(), D154–D158.
26. Lu, T.P. et al. (2012) miRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS One, 7, e42390.
27. Hasemeier, B. et al. (2008) Reliable microRNA profiling in routinely pro- cessed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology. BMC Biotechnol., 8, 90.
28. Xi, Y. et al. (2007) Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA, 13, 1668–1674.
29. Zhang, X. et al. (2008) An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J. Mol. Diagn., 10, 513–519.
30. Nam, E.J. et al. (2016) Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue. Oncotarget, 7, 70524–70534.
31. Feng, M. et al. (2011) Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene, 30, 2242–2251.
32. Chan, J.K. et al. (2014) MiR-378 as a biomarker for response to anti- angiogenic treatment in ovarian cancer. Gynecol. Oncol., 133, 568–574.
33. Chen, L.T. et al. (2012) MicroRNA-378 is associated with non-small cell lung cancer brain metastasis by promoting cell migration, invasion and tumor angiogenesis. Med. Oncol., 29, 1673–1680.
34. Xu, Z.H. et al. (2018) miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2. Biomed. Pharmacother., 107, 1410–1417.
35. Li, H. et al. (2014) Clinical and biological significance of miR-378a-3p and miR-378a-5p in colorectal cancer. Eur. J. Cancer, 50, 1207–1221.
36. Scapoli, L. et al. (2010) MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int. J. Immunopathol. Pharmacol., 23, 1229–1234.
37. Bisio, A. et al. (2013) Identification of new p53 target microRNAs by bio- informatics and functional analysis. BMC Cancer, 13, 552.
38. Yeh, T.C. et al. (2016) mir-151-3p targets TWIST1 to repress migration of human breast cancer cells. PLoS One, 11, e0168171.
39. Fukumoto, I. et al. (2015) MicroRNA expression signature of oral squa- mous cell carcinoma: functional role of microRNA-26a/b in the modu- lation of novel cancer pathways. Br. J. Cancer, 112, 891–900.
40. Lin, Y. et al. (2013) miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett., 587, 2467–2473.
41. Chang, L. et al. (2017) miR-26a-5p suppresses tumor metastasis by regulating EMT and is associated with prognosis in HCC. Clin. Transl. Oncol., 19, 695–703.
42. Sun, J. et al. (2013) MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human esophageal squamous cell carcinoma. Med. Oncol., 30, 411.
43. Chen, Y.T. et al. (2018) Biological role and clinical value of miR-99a-5p in head and neck squamous cell carcinoma (HNSCC): a bioinformatics- based study. FEBS Open Bio, 8, 1280–1298.
44. Dobbin, Z.C. et al. (2014) Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. Oncotarget, 5, 8750–8764.
45. Boone, J.D. et al. (2015) Ovarian and cervical cancer patient derived xenografts: the past, present, and future. Gynecol. Oncol., 138, 486–491.
46. Sharifnia, T. et al. (2017) Emerging opportunities for target discovery in rare cancers. Cell Chem. Biol., 24, 1075–1091.
47. Nagamitsu, Y. et al. (2016) Profiling analysis of circulating microRNA expression in cervical cancer. Mol. Clin. Oncol., 5, 189–194.
48. Takeshita, N. et al. (2013) Serum microRNA expression profile: miR- 1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br. J. Cancer, 108, 644–652.
49. Redova, M. et al. (2012) Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med., 10, 55.
50. Liu, H. et al. (2012) Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett., 316, 196–203.